Clinical Trials Logo

Glomerulonephritis, IGA clinical trials

View clinical trials related to Glomerulonephritis, IGA.

Filter by:

NCT ID: NCT00498368 Completed - IgA Nephropathy Clinical Trials

Rituximab in Progressive IgA Nephropathy

Start date: February 2009
Phase: Phase 4
Study type: Interventional

Recent clinical success in the use of Rituximab in the treatment of Lupus nephritis and other forms immune complex glomerulonephritis has led to its investigation in the treatment of IgA nephropathy. Because IgA class antibodies have comparatively short half-lives and that deposition of polymeric forms of IgA contributes to glomerular injury, we speculate that the reduction of circulating IgA may reduce proteinuria and injury in patients with IgA nephropathy. Moreover, the absence of prospective trials in the treatment of IgA disease and the lack of consensus for long-term treatment, the superior side-effect profile of this form of therapy may lead to significant advances in the treatment of this prevalent from of glomerulonephritis.

NCT ID: NCT00446459 Completed - Clinical trials for Kidney Failure, Chronic

Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.

Start date: April 2006
Phase: Phase 2
Study type: Interventional

This is a 12-month, phase II, prospective, open label study, to evaluate the effect of mycophenolate mofetil (MMF) among patients on the kidney transplant list with high Panel of Reactive Antibody (PRA) levels. On average, increasing the PRA from 0 to 50% specifically in the Washington Organ Procurement Organization (OPO) increases the waiting time from 3 to 6 years. Spontaneous decreases in the PRA rarely occur and is associated with a decreased chance for transplantation and a decreased rate of survival.

NCT ID: NCT00446251 Completed - Clinical trials for Kidney Failure, Chronic

Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant

Start date: December 2006
Phase: Phase 2
Study type: Interventional

This is a 12-month phase 2, prospective, open label study to evaluate the effect of rituximab with mycophenolate mofetil (MMF)on the PRA of 14 highly sensitized patients who just completed an 8 month trial of MMF treatment alone. PRA values obtained at study enrollment and at 6 and 12 months on combined therapy as well as the rates of transplant will be compared and evaluated using descriptive analysis.

NCT ID: NCT00426348 Completed - IGA Nephropathy Clinical Trials

A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy

Start date: May 2007
Phase: Phase 4
Study type: Interventional

a statement of the study hypothesis:the effect of valsartan in patients with IgA nephropathy have been proved,and the efficacy of probucol in combination with valsartan is to be proved in patients with IgA nephropathy. This is a prospective randomized controlled, double blinded pilot study to identify the efficacy of probucol in combination with valsartan in patients with IgA nephropathy. The renal function deterioration will be the primary outcome studied. The expected study duration will be 36 months.

NCT ID: NCT00396721 Completed - IGA Nephropathy Clinical Trials

Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy

SIREPNA
Start date: January 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test in a pilot trial the efficacy and tolerance of sirolimus oral (at low doses) in patient to treat poor-prognosis IgA Nephropathy.

NCT ID: NCT00367562 Completed - IGA Nephropathy Clinical Trials

Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy

Start date: January 1996
Phase: Phase 4
Study type: Interventional

TO ASSESS THE EFFICACY OF THE RENIN ANGIOTENSIN SYSTEM PLUS STEROIDS TO DECREASE THE AMOUNT OF PROTEINURIA IN IGA NEPHROPATHY

NCT ID: NCT00319761 Completed - IGA Nephropathy Clinical Trials

Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy

Start date: May 2006
Phase: Phase 4
Study type: Interventional

Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis in the world. A wealth of literature suggests that vitamin D and its analogs have profound effects on immune system function and glomerular mesangial cell proliferation. Calcitriol, an active form of vitamin D, is commonly used for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney diseases. Therefore, the investigators plan to conduct a open-label single-arm study to evaluate the safety and efficacy of calcitriol in the treatment of IgA nephropathy. Ten patients with biopsy-proven IgA nephropathy and persistent proteinuria despite conventional therapy will be recruited. They will be treated with calcitriol for 12 weeks. Proteinuria, renal function, serum and urinary inflammatory markers will be monitored. This study will explore the potential anti-proteinuric and anti-inflammatory effects of calcitriol in the treatment of IgA nephropathy, which is a major cause of dialysis-dependent renal failure.

NCT ID: NCT00301600 Completed - IGA Nephropathy Clinical Trials

Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy

Start date: January 2003
Phase: N/A
Study type: Interventional

A single-center random parallel study to compare the efficacy and safety of Mycophenolate mofetil versus intravenous Cyclophosphamide pulses in the treatment of crescentic IgA nephropathy

NCT ID: NCT00006137 Completed - Clinical trials for IGA Glomerulonephritis

Pilot Study of Enalapril and Renal Function in Patients With IgA Nephropathy

Start date: May 2000
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Determine the most sensitive outcome measures (functional or morphological) of a progressive renal injury in patients with IgA nephropathy. II. Determine which of these patients are destined to progress to further injury in order to target them for therapy. III. Elucidate the determinants of progression in those patients who exhibit evidence of either increasing impairment of ultrafiltration capacity or ongoing destruction of nephrons.

NCT ID: NCT00004448 Completed - Clinical trials for IGA Glomerulonephritis

Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy

Start date: November 1997
Phase: Phase 2
Study type: Interventional

OBJECTIVES: Evaluate the efficacy of alternate day prednisone versus daily fish oil supplements in slowing or preventing the decline in renal function in children, adolescents, and young adults with moderate to severe immunoglobulin A nephropathy.